Quoin Pharma reports FY2022 net loss of $9.4M; advances QRX003 trials for Netherton Syndrome

Quoin Pharmaceuticals, Ltd.

FY2022 net loss $9.4M; Q4 net loss $2.0M; cash & marketable securities $12.9M at year-end.
Dosed first patient in double-blinded placebo-controlled study of QRX003 for Netherton Syndrome.
Initiated second clinical trial of QRX003 in Netherton patients on off-label systemic therapy (FDA cleared).
Completed public offering post-quarter with ~$6M net proceeds, extending cash runway into H2 2024.
Working toward clinical testing in Australia for Scleroderma/Netherton programs in H2 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Quoin Pharmaceuticals, Ltd. reported fourth quarter and full year of 2022 results: net income Net loss for the quarter ended December 31, 2022 was approximately $2.0 million. Net loss for the year ended December 31.

Period: fourth quarter and full year of 2022
Net income: Net loss for the quarter ended December 31, 2022 was approximately $2.0 million. Net loss for the year ended December 31
Result: reported results

Exact text from the filing

Net loss for the quarter ended December 31, 2022 was approximately $2.0 million. Net loss for the year ended December 31, 2022 was approximately $9.4 million.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Quoin Pharmaceuticals, Ltd. filing history →

Source: SEC EDGAR

accession 0001104659-23-030189

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.